University of Utah

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Utah sits in the top decile of US sponsors by registered trial count (#40 of 15,742 sponsors by registered trial count).

818 total trials 138 currently recruiting 492 completed early-phase tilt top decile by trial count

University of Utah: 818 sponsored US clinical trials, 138 recruiting.

University of Utah sponsors 818 registered US clinical trials on ClinicalTrials.gov, 138 of them currently recruiting, and 492 completed. 45 of these trials are in Phase 3-4 (later-stage) and 268 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Low Back Pain, with 8 trials.

Top-decile sponsor footprint

University of Utah ranks in the top decile of sponsors by registered trial count (#40 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 41/100

492 of 611 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

818 total, page 9 of 17

TERMINATED Phase 1

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

NCT03276676

COMPLETED Phase 2

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

NCT03534804

COMPLETED

Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects

NCT03466736

TERMINATED Phase 2

Amitriptyline in Treating Hypoglycemia

NCT03591458

TERMINATED NA

Incidence of Diarrhea Using High and Low Osmolality Enteral Tube Feeding in Critically Ill Surgical Patients

NCT03487744

COMPLETED NA

Building Social Skills With Interdisciplinary Process Drama in ASD

NCT03536351

COMPLETED NA

Autophagy Maintains Vascular Function Through a Novel Glycolysis-linked Pathway Regulating eNOS

NCT04200560

COMPLETED NA

Blood and Muscle Response to Cheddar Cheese in Healthy Adults

NCT04660877

COMPLETED Phase 1

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

NCT03200587

TERMINATED Phase 1

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

NCT03407976

COMPLETED NA

Psychosocial Support for Pre-operative Pain and Distress

NCT03665727

COMPLETED NA

Gaze and Postural Stability in Multiple Sclerosis

NCT03521557

COMPLETED Phase 1

Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2

NCT03416348

COMPLETED

Measuring Postoperative Mobility, Gait Symmetry and Feedback Following TJA

NCT03673293

TERMINATED NA

Serving Women Using Opioids During Pregnancy

NCT03552120

TERMINATED Phase 1

Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma

NCT03382886

TERMINATED Phase 2

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

NCT03303950

COMPLETED Early Phase 1

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

NCT03516656

TERMINATED NA

Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia

NCT03532555

COMPLETED NA

The Effect of Electronic Informed Consent Information (EICI) on Residual Newborn Specimen Research

NCT03141307

COMPLETED

Group Therapy For Dementia Caregivers At Risk For Complicated Grief

NCT03177772

COMPLETED

Noninvasive Measurements of Renal Perfusion During Cardiac Surgery

NCT03335865

COMPLETED Phase 2

Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

NCT03304418

COMPLETED Phase 2

Fatigue Interventions in Cancer (Exercise Intervention)

NCT03421782

TERMINATED Phase 1

Contrast-Enhanced Ultrasound for Kidney Transplant

NCT02911714

COMPLETED Early Phase 1

Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)

NCT03215940

TERMINATED Phase 2

Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment

NCT02317783

TERMINATED Phase 1

Merestinib on Bone Metastases in Subjects With Breast Cancer

NCT03292536

TERMINATED Phase 2

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

NCT03259425

COMPLETED NA

The Bronchiolitis Follow-up Intervention Trial

NCT03354325

TERMINATED Phase 4

Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness?

NCT03382925

COMPLETED Phase 2

Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer

NCT03345420

TERMINATED Phase 2

Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma

NCT03190213

COMPLETED NA

Efficacy of 1540 Nanometer Erbium Glass Laser to Improve Benign Dermatofibromas

NCT03392935

COMPLETED Phase 2

Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma

NCT03339349

COMPLETED Phase 3

Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study

NCT03306992

TERMINATED NA

Validation of Frontal EEG to Formal Polysomnography in the ICU

NCT03322371

COMPLETED NA

Audiovisual Distraction for Patients Undergoing Total Knee or Hip Replacement Surgery

NCT03191838

COMPLETED

Sleep/Wake Protocol Implementation to Improve Sleep Quality in the ICU

NCT03313115

COMPLETED NA

Behavioral Interventions for Chronic Pain and Opioid-Related Problems

NCT03298269

COMPLETED NA

Community Pharmacists and Opioid Misuse

NCT03149718

COMPLETED Phase 2

Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients

NCT03251963

COMPLETED Phase 4

Comparative Trial Via Tranforaminal Approach Versus Epidural Catheter Via Interlaminar Approach

NCT03382821

TERMINATED Phase 2

Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)

NCT01968590

COMPLETED NA

Dissecting De-automatization

NCT03456505

COMPLETED NA

Collaborative Care for Infants at Risk

NCT03199326

COMPLETED NA

SymptomCare@Home: Deconstructing an Effective Symptom Management Intervention

NCT02779725

COMPLETED NA

Short Message Service Based Patient Education in Spine Patients

NCT04458428

COMPLETED Phase 1

Oxandrolone in Healthy Adults: A Relative Bioavailability Study

NCT03218631

COMPLETED Phase 2

Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery

NCT03212365

← Previous Page 9 of 17 Next →

Phase Distribution

PhaseTrial count
Phase 1 145
Phase 2 123
Phase 3 18
Phase 4 27

What is open in the University of Utah pipeline

138 recruiting of 818 indexed (17% open); 492 completed (60%).

Phase mix: 45 late (III/IV) vs 268 early (I/II) (early-phase heavy).

Top condition: Low Back Pain (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Utah: open-pipeline peers nationwide

Peers matched on 818 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

University of Utah sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share University of UtahUniversity of Texas Southwestern Medical CenterUniversity of ChicagoDana-Farber Cancer InstituteUniversity of California, San DiegoUniversity of HawaiiPenn State UniversityAdventHealthCSL Behring
University of Utah sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Utah sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 818 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this University of Utah page

818 registered trials is a research-attention snapshot, not an endorsement of University of Utah or any single study.

  • 138 of University of Utah's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Low Back Pain is the condition University of Utah studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Low Back Pain trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Utah pipeline card: 818 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.